세계의 전립선암 치료 시장 보고서(2025년)

Prostate Cancer Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,668,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,638,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,609,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

전립선암 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 8.7%의 연평균 성장률을 기록해 181억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 신흥국의 의료비 지출 증가, 암 치료에 대한 투자 증가, 첨단 영상 진단 및 진단 도구의 보급, 최소침습적 및 비수술적 치료의 채택 확대 등의 요인에 기인하는 것으로 분석됩니다. 예측 기간 동안 주요 동향으로는 표적 암 치료의 발전, 정밀 암 치료의 통합, 기술을 활용한 영상 진단 도구의 개발, 방사성 리간드를 이용한 치료의 발전, 전립선암에 대한 면역 치료의 지속적인 발전 등을 들 수 있습니다.

전립선암 발병률의 증가는 전립선암 치료 시장의 성장을 촉진할 것으로 예상됩니다. 전립선암은 전립선에 악성 세포가 형성되는 질환으로 주로 고령의 남성이 발병하는 질환입니다. 전립선암 발병률 증가는 고령화가 주요 원인이며, 나이가 들수록 발병 위험이 크게 증가하기 때문입니다. 평균 수명이 길어진 것도 이 질환에 걸릴 만큼 오래 사는 남성이 늘어났다는 것을 의미합니다. 전립선암 치료는 수술, 방사선 요법, 호르몬 요법, 면역요법과 같은 새로운 치료법을 통해 암세포를 표적으로 삼아 진행을 늦추고 삶의 질을 향상시킴으로써 전립선암을 관리하는 것을 목표로 하고 있습니다. 예를 들어, 2024년 10월 영국 국민보건서비스(NHS)는 2022년 남성 암 진단이 16만 7,917건에서 18만 877건으로 7% 증가했다고 보고했습니다. 이 증가의 대부분은 전립선암으로 인한 것으로, 25% 이상 증가하여 5 만 4,732 건에 달했습니다. 이러한 전립선암 발병률의 증가는 전립선암 치료 시장의 성장을 견인하고 있습니다.

전립선암 치료제 시장의 주요 업체들은 환자의 순응도와 치료 결과를 높이기 위해 진행성 전립선암을 위한 1일 1회 경구용 약물과 같은 혁신적인 솔루션을 도입하고 있습니다. 이러한 경구용 약물은 매일 복용하며, 암세포에 대한 테스토스테론의 작용을 억제하여 전이성 거세저항성 전립선암을 관리합니다. 예를 들어, 2024년 1월 인도 제약사 자이더스 라이프사이언스는 진행성 전립선암 환자를 위한 인도 최초의 레고릭스(Rergolix) 성분의 경구용 1일 1회 복용 정제 렉시고(Rexigo)를 출시했습니다. 주사를 통한 호르몬 요법을 대체할 수 있는 편리하고 합리적인 가격의 이 치료법은 테스토스테론을 빠르게 억제하고 암의 성장을 억제하며 심혈관계 안전성 프로파일을 개선하여 효과를 발휘합니다. 이 경구용 치료제는 의료진이 주사 치료를 하지 않아도 되므로 환자의 편의성을 향상시킬 수 있습니다. 이번 출시는 인도 전립선암 치료의 큰 진전이며, 환자와 의사에게 안전하고 비용 효율적인 새로운 치료 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 전립선암 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 전립선암 치료 시장 : 성장률 분석
• 세계의 전립선암 치료 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 전립선암 치료 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 전립선암 치료 전체 시장(TAM)

제6장 시장 세분화

• 세계의 전립선암 치료 시장 : 요법별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 호르몬요법
• 화학요법
• 면역요법
• 표적요법
• 기타 요법
• 세계의 전립선암 치료 시장 : 약물 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 안드로겐 수용체 억제제
• GnRH 수용체 길항제
• PARP 억제제
• 면역관문억제제
• 기타
• 세계의 전립선암 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 주사
• 세계의 전립선암 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 판매
• 세계의 전립선암 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 클리닉
• 병원
• 기타
• 세계의 전립선암 치료 시장, 호르몬요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 황체 형성 호르몬 방출 호르몬(LHRH) 작용제
• Lhrh 길항제
• 항안드로겐
• 안드로겐 합성 억제제
• 세계의 전립선암 치료 시장, 화학요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 도세탁셀
• 카바지탁셀
• 미토잔트론
• 병용 화학요법 요법
• 세계의 전립선암 치료 시장, 면역요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 시풀루셀-T
• 면역관문억제제
• 암 백신
• 사이토카인 기반 요법
• 세계의 전립선암 치료 시장, 표적요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• PARP 억제제
• 방사성 리간드 요법
• 티로신 키나아제 억제제
• 세계의 전립선암 치료 시장, 기타 요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 방사선 치료
• 뼈 표적요법
• 냉동요법
• 고강도 초점식 초음파

제7장 지역별·국가별 분석

• 세계의 전립선암 치료 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 전립선암 치료 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 전립선암 치료 시장 : 경쟁 구도
• 전립선암 치료 시장 : 기업 개요
  • Johnson & Johnson
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Novartis AG
  • AstraZeneca plc

제31장 기타 주요 기업과 혁신적 기업

• Sanofi S.A.
• Astellas Pharma Inc.
• Jiangsu Hengrui Medicine Co. Ltd.
• Telix Pharmaceuticals
• Bayer AG
• Curium Pharma SAS
• Dendreon Pharmaceuticals
• Myovant Sciences GmbH
• Clovis Oncology Inc.
• Ipsen S.A.
• Veru Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Dendreon Pharmaceuticals LLC
• Pfizer Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

• 전립선암 치료 시장, 2029년 : 새로운 기회를 제공하는 국가
• 전립선암 치료 시장, 2029년 : 새로운 기회를 제공하는 부문
• 전립선암 치료 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Prostate cancer therapeutics encompass a range of medical treatments and interventions designed to manage, control, or eliminate prostate cancer, a type of cancer that forms in the prostate gland of men. These therapies aim to slow disease progression, alleviate symptoms, improve quality of life, and, in some instances, achieve remission.

The primary types of therapies in prostate cancer treatment include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy is a treatment that modifies hormone levels in the body to address conditions such as cancer or hormonal imbalances. This therapy includes various drug classes such as androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and more, which can be administered either orally or through injection. These therapies are distributed via hospital pharmacies, retail pharmacies, and online sales, serving various end users, including clinics, hospitals, and other medical facilities.

The prostate cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer therapeutics market statistics, including prostate cancer therapeutics industry global market size, regional shares, competitors with a prostate cancer therapeutics market share, detailed prostate cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer therapeutics industry. This prostate cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer therapeutics market size has grown strongly in recent years. It will grow from $11.92 billion in 2024 to $13.00 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to several factors, including the rising global incidence of prostate cancer, increased awareness of early cancer screening and diagnostic programs, the growing elderly male population, and a higher demand for personalized and targeted therapies.

The prostate cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as rising healthcare expenditure in emerging economies, increasing investments in oncology drugs, greater availability of advanced imaging and diagnostic tools, and the growing adoption of minimally invasive and non-surgical treatments. Key trends in the forecast period include advancements in targeted cancer therapies, the integration of precision cancer medicine, the development of technology-driven diagnostic imaging tools, progress in radioligand-based treatments, and continued advancements in immunotherapy for prostate cancer.

The increasing incidence of prostate cancer is expected to drive the growth of the prostate cancer therapeutics market. Prostate cancer, a disease where malignant cells form in the prostate gland, primarily affects older men. The rise in prostate cancer incidences is largely attributed to the aging population, as the risk of developing the disease increases significantly with age. Longer life expectancy also means more men are living long enough to develop the condition. Prostate cancer therapeutics aim to manage the disease by targeting cancer cells, slowing its progression, and improving the quality of life through treatments such as surgery, radiation, hormone therapy, and newer options such as immunotherapy. For example, in October 2024, the National Health Service (NHS) in the UK reported that cancer diagnoses among men increased by 7% in 2022, from 167,917 to 180,877 cases. A significant portion of this rise was attributed to prostate cancer, which saw a more than 25% increase, reaching 54,732 cases. This growing incidence of prostate cancer is driving the expansion of the prostate cancer therapeutics market.

Leading companies in the prostate cancer therapeutics market are introducing innovative solutions, such as oral once-a-day pills for advanced prostate cancer, to enhance patient compliance and treatment outcomes. These oral pills are taken daily and manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based pharmaceutical company, launched Rexigo, India's first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies works by rapidly suppressing testosterone, controlling cancer growth, and offering an improved cardiovascular safety profile. The oral therapy eliminates the need for injectable treatments administered by healthcare providers, offering greater convenience for patients. This launch marks a significant advancement in prostate cancer management in India, providing patients and doctors with a new, safe, cost-effective treatment option.

In June 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. The acquisition strengthens AstraZeneca's portfolio, enabling the development of next-generation radio conjugates that offer more targeted therapies, potentially replacing traditional chemotherapy and radiotherapy treatments. Fusion Pharmaceuticals, a Canada-based clinical-stage oncology company, specializes in therapies for prostate cancer, particularly targeting metastatic castration-resistant prostate cancer (mCRPC).

Major players in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prostate cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer therapeutics market consists of revenues earned by entities by providing services such as medical consultation services, diagnostic services, psychosocial support, clinical trials access, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer therapeutics market also includes sales of hormone therapy medications, chemotherapy drugs, immunotherapy products, and targeted therapy drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy; Other Therapies
• 2) By Drug Class: Androgen Receptor Inhibitors; GnRH Receptor Antagonists; PARP Inhibitors; Immune Checkpoint Inhibitors; Other Drug Classes
• 3) By Route Of Administration: Oral; Injectable
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Sales
• 5) By End User: Clinics; Hospitals; Other End Users
• Subsegments:
• 1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists; LHRH Antagonists; Anti-Androgens; Androgen Synthesis Inhibitors
• 2) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Combination Chemotherapy Regimens
• 3) By Immunotherapy: Sipuleucel-T; Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine-Based Therapies
• 4) By Targeted Therapy: PARP Inhibitors; Radioligand Therapy; Tyrosine Kinase Inhibitors
• 5) By Other Therapies: Radiotherapy; Bone-Targeted Therapies; Cryotherapy; High-Intensity Focused Ultrasound
• Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Therapeutics Market Characteristics

3. Prostate Cancer Therapeutics Market Trends And Strategies

4. Prostate Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Prostate Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Therapeutics Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Therapeutics Total Addressable Market (TAM)

6. Prostate Cancer Therapeutics Market Segmentation

• 6.1. Global Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Other Therapies
• 6.2. Global Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Androgen Receptor Inhibitors
• GnRH Receptor Antagonists
• PARP Inhibitors
• Immune Checkpoint Inhibitors
• Other Drug Classes
• 6.3. Global Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Prostate Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Sales
• 6.5. Global Prostate Cancer Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Other End Users
• 6.6. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
• Lhrh Antagonists
• Anti-Androgens
• Androgen Synthesis Inhibitors
• 6.7. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Docetaxel
• Cabazitaxel
• Mitoxantrone
• Combination Chemotherapy Regimens
• 6.8. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sipuleucel-T
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Cytokine-Based Therapies
• 6.9. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parp Inhibitors
• Radioligand Therapy
• Tyrosine Kinase Inhibitors
• 6.10. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiotherapy
• Bone-Targeted Therapies
• Cryotherapy
• High-Intensity Focused Ultrasound

7. Prostate Cancer Therapeutics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Therapeutics Market

• 8.1. Asia-Pacific Prostate Cancer Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Therapeutics Market

• 9.1. China Prostate Cancer Therapeutics Market Overview
• 9.2. China Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Therapeutics Market

• 10.1. India Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Therapeutics Market

• 11.1. Japan Prostate Cancer Therapeutics Market Overview
• 11.2. Japan Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Therapeutics Market

• 12.1. Australia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Therapeutics Market

• 13.1. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Therapeutics Market

• 14.1. South Korea Prostate Cancer Therapeutics Market Overview
• 14.2. South Korea Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Therapeutics Market

• 15.1. Western Europe Prostate Cancer Therapeutics Market Overview
• 15.2. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Therapeutics Market

• 16.1. UK Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Therapeutics Market

• 17.1. Germany Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Therapeutics Market

• 18.1. France Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Therapeutics Market

• 19.1. Italy Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Therapeutics Market

• 20.1. Spain Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Therapeutics Market

• 21.1. Eastern Europe Prostate Cancer Therapeutics Market Overview
• 21.2. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Therapeutics Market

• 22.1. Russia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Therapeutics Market

• 23.1. North America Prostate Cancer Therapeutics Market Overview
• 23.2. North America Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Therapeutics Market

• 24.1. USA Prostate Cancer Therapeutics Market Overview
• 24.2. USA Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Therapeutics Market

• 25.1. Canada Prostate Cancer Therapeutics Market Overview
• 25.2. Canada Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Therapeutics Market

• 26.1. South America Prostate Cancer Therapeutics Market Overview
• 26.2. South America Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Therapeutics Market

• 27.1. Brazil Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Therapeutics Market

• 28.1. Middle East Prostate Cancer Therapeutics Market Overview
• 28.2. Middle East Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Therapeutics Market

• 29.1. Africa Prostate Cancer Therapeutics Market Overview
• 29.2. Africa Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Therapeutics Market Competitive Landscape
• 30.2. Prostate Cancer Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Astellas Pharma Inc.
• 31.3. Jiangsu Hengrui Medicine Co. Ltd.
• 31.4. Telix Pharmaceuticals
• 31.5. Bayer AG
• 31.6. Curium Pharma SAS
• 31.7. Dendreon Pharmaceuticals
• 31.8. Myovant Sciences GmbH
• 31.9. Clovis Oncology Inc.
• 31.10. Ipsen S.A.
• 31.11. Veru Inc.
• 31.12. Bristol-Myers Squibb Company
• 31.13. F. Hoffmann-La Roche Ltd
• 31.14. Dendreon Pharmaceuticals LLC
• 31.15. Pfizer Inc.

32. Global Prostate Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Therapeutics Market

34. Recent Developments In The Prostate Cancer Therapeutics Market

35. Prostate Cancer Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료